Pulsatile secretion of luteinizing hormone and prolactin in lactating and nonlactating women and the response to naltrexone.
To investigate the mechanisms responsible for the postpartum suppression of reproductive function, LH and PRL levels were determined at 10-min intervals for 8 h in 10 lactating women, in 10 nonlactating women treated with bromocriptine, and in 5 nonpuerperal women. The lactating women were studied on postpartum day 7 (n = 5) or between days 28 and 35 (n = 5). All nonlactating women were studied on day 7. Five of them were treated with the opioid antagonist naltrexone to evaluate the role of endogenous opioids. By using a specific LH assay which does not cross-react with hCG, we were able to measure pulsatile LH secretion in the early puerperium for the first time. On day 7, LH levels were below the detection limit in both lactating and nonlactating women, hence no pulses could be detected. Chronic opioid blockade in bromocriptine-treated non-lactating women did not result in increased LH levels. Pulsatile LH secretion was present between days 28 and 35 of lactation, although pulse amplitude (P less than 0.05) and mean LH level (P less than 0.05) were lower than in nonpuerperal women. Mean LH in lactating women was negatively correlated with mean PRL (-0.87, P less than 0.05). Deconvolution analysis of the PRL responses to suckling revealed that PRL was secreted in distinct bursts, separated by intervals of secretory quiescence. Mean duration of PRL bursts was 40 +/- 4 min and the maximum secretory rate was reached around the end of suckling. We conclude that pulsatile LH secretion is completely suppressed during early lactation and partially suppressed during late lactation. Because the duration of suckling was similar, the relatively strong suppression during the early puerperium must be due to additional inhibitory factors. It has been suggested that endogenous opioids are involved in this process, but our results in puerperal women do not support this hypothesis.
Kremer
J A
JA
Department of Obstetrics and Gynecology, St. Radboud University Hospital, Nijmegen, The Netherlands.
Borm
G
G
Schellekens
L A
LA
Thomas
C M
CM
Rolland
R
R
D000328:Adult; D001971:Bromocriptine; D006063:Chorionic Gonadotropin / Q000097:blood; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005498:Follicular Phase; D006801:Humans; D007774:Lactation / Q000502:physiology*; D007986:Luteinizing Hormone / Q000097:blood / Q000378:metabolism*; D009271:Naltrexone / Q000494:pharmacology*; D010507:Periodicity; D049590:Postpartum Period / Q000097:blood*; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood / Q000378:metabolism*
D006063:Chorionic Gonadotropin; D001971:Bromocriptine; D011374:Progesterone; D004958:Estradiol; D009271:Naltrexone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone